Cancer/Tumor Profiling Market Synopsis

Cancer/Tumor Profiling Market Size Was Valued at USD 10.1 Billion in 2023, and is Projected to Reach USD 23.4 Billion by 2032, Growing at a CAGR of 9.8% From 2024-2032.

Cancer/tumor profiling allows elaborate examination of the tumor and analyzes the genetic features of the object. It has however gained importance in the recent past due to the fact that the various profiling techniques for cancer can reveal a lot about the cancer tumor. The information got from cancer profiling is used to develop the correct course of any treatment for any person with cancer. Cancer has become prevalent throughout the world and consequently; there is need to perform molecular profile to diagnose cancer. Notably, the rise in knowledge concerning various cancers, including breast, oral, pancreatic, and many others, contributes to the market expansion. Cancer profiling methods employed by oncologists allow them to make distinctions at the molecular level concerning cancer cells.

• Cancer profiling is done through techniques for example next generation sequencing NGS, polymerase chain reaction PCR, in situ Hybridization ISH, immunohistochemistry IHC, microarray and others. The NGS segment which is the next-generation sequencing has the biggest market share and oncologist is seen to embrace the NGS technology in cancer profiling. Covers a high tumor sample or fresh frozen FNAs or CTCs; NGS is capable of deep sequencing of a given tumor biopsy. This helps in creating a detailed profile of the cancer through the identification of mutations hence increasing the utilization of NGS. However, fluorescence in situ hybridization has been recently applied in the diagnosis, because the sensitivity is higher than NGS. Currently, personalized medicine segment is expected to fuel the global market for FISH and NGS and the use of profiling panels in the routine diagnostic procedure is likely to rise in the years to come.
• The techniques used in cancer profiling are genomics, proteomics, epigenetic, and metabolite profiling. Protomics is the second largest technique used in the cancer profiling market because the determination of the extent of proteins present in malignant tumour through proteomic profiling techniques is highly significant in the effective profiling of cancer. Protein Quantitative trait is important to aid in the right diagnosis as well as aid in therapy of the cancer patients. The global incidents of breast cancers and the growth in concern towards targeted treatment being provided for cancer patients should fuel the growth in the near future.
• The current global market is mainly propelled by the rising need for cancer profiling method, especially among oncologists in the diagnosis and treatment of cancer and particularly in the ability to forecast fate to targeted therapy. Besides, growth in usage of cancer biomarkers for tumor, increased occurrence of cancer globally, and advanced usage of next generation sequencing technique for cancer have contributed to the market growth. Nevertheless, elevated cost on biomarkers and fewer specialized personnel or oncologists acquainted with tumor profiling act as a hindrance to the growth of the market.

Cancer/Tumor Profiling Market Trend Analysis

Rising Cancer Rates & Increasing Awareness

• The escalating rate of cancer across the world is the most significant factor driving the development of the market. The essence of cancer profiling methods by oncologists in the developing economies is establishing the pattern for the growth of the market.
• Cancer is unfortunatley on the rise globally attributed to issues such as increase in the world’s population, aging, and alteration of the populace’s lifestyles. This, along with an increasing culture of educated populations towards cancer, its diagnosis and treatment solutions is opening up a huge market for tumor profiling services
• World health organization report of cancer in 2021 revealed that cancer was the leading cause of death with 13.6% million deaths globally. In the global context, trends in cancer incidence have been identified to be on the rise due to the growing population of aging people, changes in global diet, and other aspects of an individual’s environment. This results in increased need for adequate cancer diagnosis and treatment that will be suitable to different patients, which in turns creates the need for effective tumor profiling technologies.

Government Investments in Healthcare Infrastructure

• Market growth rate will be boosted by the federal governments’ increased funding of the same. Also, the increasing globalisation and liberalisation of the healthcare industry that has been stimulated by both public and private sectors particularly in the developing regions will foster market growth prospects. Also, the high return on investments guaranteed by the resurgent research activities and the growing personnel in the technologies exploring the field of cancer/tumor profiling will also benefit the market. Conversing, the boosting in the use of the cancer biomarkers for diagnosing cancer/tumor, global personal disposable income level increase in the number of technologically driven products to the hospitals, growing investment for the advanced medical products and instruments, rising need for Point of Care diagnostics, and increasing concern of personalized medicines among people have a positive impact on the market CAGR.

Cancer/Tumor Profiling Market Segment Analysis:

Cancer/Tumor Profiling Market Segmented based on Type, Technology, and Application.

By Type, Genomic segment is expected to dominate the market during the forecast period

• Depending on Type, the market is divided into Genomic, Proteomic, Epigenetic, and Metabolomic. Of all the tumor profiling types, genomic profiling is predicted to be the largest and have the highest market share between yr. It involves identification of all the genes within the tumor, which gives information on the tumor’s genetic structure and abnormalities.
• Genomic profiling has always maintained a prominence in the management of cancer, thanks to the increased use of new genomic technologies in oncology hence its leading position in the Cancer/Tumor Profiling Market.

By Technology, Next Generation Sequencing (NGS) segment held the largest share in 2023

• Depending on the Technology the market can be segmented into Next Generation Sequencing, Polymerase Chain Reaction, Immunohistochemistry, In-Situ Hybridization, Mass Spectrometry and Microarray. The global market share distribution for tumor profiling technology demonstrates that Next Generation Sequencing (NGS) holds the largest market share. Its capacity to provide a holistic assessment of genes and ability to detect mutations makes it a popular tool among researchers and clinicians. Tumor biology can be elucidated more comprehensively by NGS and the therapeutic approaches for patients can be managed accordingly for better prognosis.

Cancer/Tumor Profiling Market Regional Insights:

North America is Expected to Dominate the Market Over the Forecast period

• North America has been identified as having leadership research organizations and prominent pharmaceutical manufacturers as the key professionals in spearheading the development of tumor profiling technologies. These countries’ institutions are the engines that drive research and development in the field. Fine academic medical centers and clinical laboratories, having access to advanced detection instrumentation, define North America’s status as the world’s leading region in intricate tumor profiling. They have the superior means for in-depth examination of events and patterns. Substantial awareness towards and spending on healthcare organizations and facilities across the North American region drives the increased usage of innovative tumor profiling solutions. As a financial investment, it makes it possible for the region in question to be in a position to adopt modern technology and the best especially proven techniques.
•  In North America, a favourable regulatory setting for the medical field provides clear channels to new technologies which enables faster development and access to various methods of tumor profiling. This advantage enables them to be market pioneers in as far as the newest options available in the market are concerned.

Active Key Players in the Cancer/Tumor Profiling Market

• Lucence Health Inc.
• F. Hoffmann-La Roche Ltd
• Caris Life Sciences
• ACT Genomics Co., LTD
• Thermo Fisher Scientific Inc.
• Strand Life Sciences
• IMB Dx, Inc.
• Illumina, Inc.
• Guardant Health
• QIAGEN
• Ribomed Biotechnologies Inc.
• HTG Molecular Diagnostics, Inc.
• NanoString
• NeoGenomics Laboratories
• Exact Sciences Corporation
• Other Key Players

Key Industry Developments in the Cancer/Tumor Profiling Market:

• In May 2023, Lucence Health Inc. launched a revolutionary multi-cancer early detection (MCED) blood test called LucenceINSIGHT, which is the first ever MCED test in the world It is a ctDNA-based liquid biopsy test that identifies ten common cancers via blood sampling.
•  In May 2022, Qiagen Company released the Thera screen EGFR Plus RGQ PCR Kit that is an in-vitro diagnostic test to provide sensitive EGFR mutation analysis. This helps oncologist to provide appropriate care to the patients diagnosed with NSCLC.

Chapter 1: Introduction
 1.1 Scope and Coverage

Chapter 2:Executive Summary

Chapter 3: Market Landscape
 3.1 Market Dynamics
  3.1.1 Drivers
  3.1.2 Restraints
  3.1.3 Opportunities
  3.1.4 Challenges
 3.2 Market Trend Analysis
 3.3 PESTLE Analysis
 3.4 Porter's Five Forces Analysis
 3.5 Industry Value Chain Analysis
 3.6 Ecosystem
 3.7 Regulatory Landscape
 3.8 Price Trend Analysis
 3.9 Patent Analysis
 3.10 Technology Evolution
 3.11 Investment Pockets
 3.12 Import-Export Analysis

Chapter 4: Cancer/Tumor Profiling Market by Type
 4.1 Cancer/Tumor Profiling Market Snapshot and Growth Engine
 4.2 Cancer/Tumor Profiling Market Overview
 4.3 Genomic
  4.3.1 Introduction and Market Overview
  4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.3.3 Key Market Trends, Growth Factors and Opportunities
  4.3.4 Genomic: Geographic Segmentation Analysis
 4.4 Proteomic
  4.4.1 Introduction and Market Overview
  4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.4.3 Key Market Trends, Growth Factors and Opportunities
  4.4.4 Proteomic: Geographic Segmentation Analysis
 4.5 Epigenetic
  4.5.1 Introduction and Market Overview
  4.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.5.3 Key Market Trends, Growth Factors and Opportunities
  4.5.4 Epigenetic: Geographic Segmentation Analysis
 4.6 Metabolomic
  4.6.1 Introduction and Market Overview
  4.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.6.3 Key Market Trends, Growth Factors and Opportunities
  4.6.4 Metabolomic: Geographic Segmentation Analysis

Chapter 5: Cancer/Tumor Profiling Market by Technology
 5.1 Cancer/Tumor Profiling Market Snapshot and Growth Engine
 5.2 Cancer/Tumor Profiling Market Overview
 5.3 Next-Generation Sequencing
  5.3.1 Introduction and Market Overview
  5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.3.3 Key Market Trends, Growth Factors and Opportunities
  5.3.4 Next-Generation Sequencing: Geographic Segmentation Analysis
 5.4 Polymerase Chain Reaction
  5.4.1 Introduction and Market Overview
  5.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.4.3 Key Market Trends, Growth Factors and Opportunities
  5.4.4 Polymerase Chain Reaction: Geographic Segmentation Analysis
 5.5 Immunohistochemistry
  5.5.1 Introduction and Market Overview
  5.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.5.3 Key Market Trends, Growth Factors and Opportunities
  5.5.4 Immunohistochemistry: Geographic Segmentation Analysis
 5.6 In-Situ Hybridization
  5.6.1 Introduction and Market Overview
  5.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.6.3 Key Market Trends, Growth Factors and Opportunities
  5.6.4 In-Situ Hybridization: Geographic Segmentation Analysis
 5.7 Mass Spectrometry
  5.7.1 Introduction and Market Overview
  5.7.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.7.3 Key Market Trends, Growth Factors and Opportunities
  5.7.4 Mass Spectrometry: Geographic Segmentation Analysis
 5.8 Microarray
  5.8.1 Introduction and Market Overview
  5.8.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.8.3 Key Market Trends, Growth Factors and Opportunities
  5.8.4 Microarray: Geographic Segmentation Analysis

Chapter 6: Cancer/Tumor Profiling Market by Application
 6.1 Cancer/Tumor Profiling Market Snapshot and Growth Engine
 6.2 Cancer/Tumor Profiling Market Overview
 6.3 Diagnosis
  6.3.1 Introduction and Market Overview
  6.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  6.3.3 Key Market Trends, Growth Factors and Opportunities
  6.3.4 Diagnosis: Geographic Segmentation Analysis
 6.4 Prognosis
  6.4.1 Introduction and Market Overview
  6.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  6.4.3 Key Market Trends, Growth Factors and Opportunities
  6.4.4 Prognosis: Geographic Segmentation Analysis
 6.5 Treatment Selection
  6.5.1 Introduction and Market Overview
  6.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  6.5.3 Key Market Trends, Growth Factors and Opportunities
  6.5.4 Treatment Selection: Geographic Segmentation Analysis
 6.6 Patient Monitoring
  6.6.1 Introduction and Market Overview
  6.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  6.6.3 Key Market Trends, Growth Factors and Opportunities
  6.6.4 Patient Monitoring: Geographic Segmentation Analysis
 6.7 Research
  6.7.1 Introduction and Market Overview
  6.7.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  6.7.3 Key Market Trends, Growth Factors and Opportunities
  6.7.4 Research: Geographic Segmentation Analysis

Chapter 7: Company Profiles and Competitive Analysis
 7.1 Competitive Landscape
  7.1.1 Competitive Benchmarking
  7.1.2 Cancer/Tumor Profiling Market Share by Manufacturer (2023)
  7.1.3 Industry BCG Matrix
  7.1.4 Heat Map Analysis
  7.1.5 Mergers and Acquisitions
  
 7.2 LUCENCE HEALTH INC
  7.2.1 Company Overview
  7.2.2 Key Executives
  7.2.3 Company Snapshot
  7.2.4 Role of the Company in the Market
  7.2.5 Sustainability and Social Responsibility
  7.2.6 Operating Business Segments
  7.2.7 Product Portfolio
  7.2.8 Business Performance
  7.2.9 Key Strategic Moves and Recent Developments
  7.2.10 SWOT Analysis
 7.3 F. HOFFMANN-LA ROCHE LTD
 7.4 CARIS LIFE SCIENCES
 7.5 ACT GENOMICS CO
 7.6 LTD
 7.7 THERMO FISHER SCIENTIFIC INC
 7.8 STRAND LIFE SCIENCES
 7.9 IMB DX INC
 7.10 ILLUMINA
 7.11 INC
 7.12 GUARDANT HEALTH
 7.13 QIAGEN
 7.14 RIBOMED BIOTECHNOLOGIES INC
 7.15 HTG MOLECULAR DIAGNOSTICS
 7.16 INC
 7.17 NANOSTRING
 7.18 NEOGENOMICS LABORATORIES
 7.19 EXACT SCIENCES CORPORATION
 7.20 OTHER MAJOR PLAYERS

Chapter 8: Global Cancer/Tumor Profiling Market By Region
 8.1 Overview
 8.2. North America Cancer/Tumor Profiling Market
  8.2.1 Key Market Trends, Growth Factors and Opportunities
  8.2.2 Top Key Companies
  8.2.3 Historic and Forecasted Market Size by Segments
  8.2.4 Historic and Forecasted Market Size By Type
   8.2.4.1 Genomic
   8.2.4.2 Proteomic
   8.2.4.3 Epigenetic
   8.2.4.4 Metabolomic
  8.2.5 Historic and Forecasted Market Size By Technology
   8.2.5.1 Next-Generation Sequencing
   8.2.5.2 Polymerase Chain Reaction
   8.2.5.3 Immunohistochemistry
   8.2.5.4 In-Situ Hybridization
   8.2.5.5 Mass Spectrometry
   8.2.5.6 Microarray
  8.2.6 Historic and Forecasted Market Size By Application
   8.2.6.1 Diagnosis
   8.2.6.2 Prognosis
   8.2.6.3 Treatment Selection
   8.2.6.4 Patient Monitoring
   8.2.6.5 Research
  8.2.7 Historic and Forecast Market Size by Country
   8.2.7.1 US
   8.2.7.2 Canada
   8.2.7.3 Mexico
 8.3. Eastern Europe Cancer/Tumor Profiling Market
  8.3.1 Key Market Trends, Growth Factors and Opportunities
  8.3.2 Top Key Companies
  8.3.3 Historic and Forecasted Market Size by Segments
  8.3.4 Historic and Forecasted Market Size By Type
   8.3.4.1 Genomic
   8.3.4.2 Proteomic
   8.3.4.3 Epigenetic
   8.3.4.4 Metabolomic
  8.3.5 Historic and Forecasted Market Size By Technology
   8.3.5.1 Next-Generation Sequencing
   8.3.5.2 Polymerase Chain Reaction
   8.3.5.3 Immunohistochemistry
   8.3.5.4 In-Situ Hybridization
   8.3.5.5 Mass Spectrometry
   8.3.5.6 Microarray
  8.3.6 Historic and Forecasted Market Size By Application
   8.3.6.1 Diagnosis
   8.3.6.2 Prognosis
   8.3.6.3 Treatment Selection
   8.3.6.4 Patient Monitoring
   8.3.6.5 Research
  8.3.7 Historic and Forecast Market Size by Country
   8.3.7.1 Bulgaria
   8.3.7.2 The Czech Republic
   8.3.7.3 Hungary
   8.3.7.4 Poland
   8.3.7.5 Romania
   8.3.7.6 Rest of Eastern Europe
 8.4. Western Europe Cancer/Tumor Profiling Market
  8.4.1 Key Market Trends, Growth Factors and Opportunities
  8.4.2 Top Key Companies
  8.4.3 Historic and Forecasted Market Size by Segments
  8.4.4 Historic and Forecasted Market Size By Type
   8.4.4.1 Genomic
   8.4.4.2 Proteomic
   8.4.4.3 Epigenetic
   8.4.4.4 Metabolomic
  8.4.5 Historic and Forecasted Market Size By Technology
   8.4.5.1 Next-Generation Sequencing
   8.4.5.2 Polymerase Chain Reaction
   8.4.5.3 Immunohistochemistry
   8.4.5.4 In-Situ Hybridization
   8.4.5.5 Mass Spectrometry
   8.4.5.6 Microarray
  8.4.6 Historic and Forecasted Market Size By Application
   8.4.6.1 Diagnosis
   8.4.6.2 Prognosis
   8.4.6.3 Treatment Selection
   8.4.6.4 Patient Monitoring
   8.4.6.5 Research
  8.4.7 Historic and Forecast Market Size by Country
   8.4.7.1 Germany
   8.4.7.2 UK
   8.4.7.3 France
   8.4.7.4 Netherlands
   8.4.7.5 Italy
   8.4.7.6 Russia
   8.4.7.7 Spain
   8.4.7.8 Rest of Western Europe
 8.5. Asia Pacific Cancer/Tumor Profiling Market
  8.5.1 Key Market Trends, Growth Factors and Opportunities
  8.5.2 Top Key Companies
  8.5.3 Historic and Forecasted Market Size by Segments
  8.5.4 Historic and Forecasted Market Size By Type
   8.5.4.1 Genomic
   8.5.4.2 Proteomic
   8.5.4.3 Epigenetic
   8.5.4.4 Metabolomic
  8.5.5 Historic and Forecasted Market Size By Technology
   8.5.5.1 Next-Generation Sequencing
   8.5.5.2 Polymerase Chain Reaction
   8.5.5.3 Immunohistochemistry
   8.5.5.4 In-Situ Hybridization
   8.5.5.5 Mass Spectrometry
   8.5.5.6 Microarray
  8.5.6 Historic and Forecasted Market Size By Application
   8.5.6.1 Diagnosis
   8.5.6.2 Prognosis
   8.5.6.3 Treatment Selection
   8.5.6.4 Patient Monitoring
   8.5.6.5 Research
  8.5.7 Historic and Forecast Market Size by Country
   8.5.7.1 China
   8.5.7.2 India
   8.5.7.3 Japan
   8.5.7.4 South Korea
   8.5.7.5 Malaysia
   8.5.7.6 Thailand
   8.5.7.7 Vietnam
   8.5.7.8 The Philippines
   8.5.7.9 Australia
   8.5.7.10 New Zealand
   8.5.7.11 Rest of APAC
 8.6. Middle East & Africa Cancer/Tumor Profiling Market
  8.6.1 Key Market Trends, Growth Factors and Opportunities
  8.6.2 Top Key Companies
  8.6.3 Historic and Forecasted Market Size by Segments
  8.6.4 Historic and Forecasted Market Size By Type
   8.6.4.1 Genomic
   8.6.4.2 Proteomic
   8.6.4.3 Epigenetic
   8.6.4.4 Metabolomic
  8.6.5 Historic and Forecasted Market Size By Technology
   8.6.5.1 Next-Generation Sequencing
   8.6.5.2 Polymerase Chain Reaction
   8.6.5.3 Immunohistochemistry
   8.6.5.4 In-Situ Hybridization
   8.6.5.5 Mass Spectrometry
   8.6.5.6 Microarray
  8.6.6 Historic and Forecasted Market Size By Application
   8.6.6.1 Diagnosis
   8.6.6.2 Prognosis
   8.6.6.3 Treatment Selection
   8.6.6.4 Patient Monitoring
   8.6.6.5 Research
  8.6.7 Historic and Forecast Market Size by Country
   8.6.7.1 Turkey
   8.6.7.2 Bahrain
   8.6.7.3 Kuwait
   8.6.7.4 Saudi Arabia
   8.6.7.5 Qatar
   8.6.7.6 UAE
   8.6.7.7 Israel
   8.6.7.8 South Africa
 8.7. South America Cancer/Tumor Profiling Market
  8.7.1 Key Market Trends, Growth Factors and Opportunities
  8.7.2 Top Key Companies
  8.7.3 Historic and Forecasted Market Size by Segments
  8.7.4 Historic and Forecasted Market Size By Type
   8.7.4.1 Genomic
   8.7.4.2 Proteomic
   8.7.4.3 Epigenetic
   8.7.4.4 Metabolomic
  8.7.5 Historic and Forecasted Market Size By Technology
   8.7.5.1 Next-Generation Sequencing
   8.7.5.2 Polymerase Chain Reaction
   8.7.5.3 Immunohistochemistry
   8.7.5.4 In-Situ Hybridization
   8.7.5.5 Mass Spectrometry
   8.7.5.6 Microarray
  8.7.6 Historic and Forecasted Market Size By Application
   8.7.6.1 Diagnosis
   8.7.6.2 Prognosis
   8.7.6.3 Treatment Selection
   8.7.6.4 Patient Monitoring
   8.7.6.5 Research
  8.7.7 Historic and Forecast Market Size by Country
   8.7.7.1 Brazil
   8.7.7.2 Argentina
   8.7.7.3 Rest of SA

Chapter 9 Analyst Viewpoint and Conclusion
9.1 Recommendations and Concluding Analysis
9.2 Potential Market Strategies

Chapter 10 Research Methodology
10.1 Research Process
10.2 Primary Research
10.3 Secondary Research